A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Inclusion Criteria

• •Participants with age greater than or equal to (\>=) 18 years with either unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF
• •Eastern Cooperative Oncology Group Performance Status 0 to 2
• •Life expectancy \>=12 weeks
• •Adequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drug
• •Female participants of childbearing potential and male participants with partners of childbearing potential must agree to always use two effective methods of contraception including at least one method with a failure rate of \<1% per year during the course of the study and for at least 6 months after completion of study treatment
• •Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential
• •Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule